<DOC>
	<DOC>NCT01198392</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.</brief_summary>
	<brief_title>Trial of S-1 Plus Cisplatin in Gastric Cancer</brief_title>
	<detailed_description>This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirmed adenocarcinoma of the stomach with inoperable locally advanced or recurrent and/or metastatic disease. Male or female. Age 18 75. Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study). Measurable disease, according to the Response Evaluation Criteria in Solid Tumours(RECIST) ECOG Performance status 0, 1 or 2 Haematological, Biochemical and Organ Function: Neutrophil count &gt;2.0 × 10 9/L, platelet count &gt; 100 ×10 9/L. Serum bilirubin&lt; 1.5 × upper limit of normal (ULN); or, AST or ALT &lt; 2.5 × ULN (or &lt; 5 × ULN in patients with liver metastases); or, alkaline phosphatase&lt; 2.5 × ULN (or &gt; 5 × ULN in patients with liver metastases,Creatinine clearance &gt; 60 mL/min. Signed informed consent. prior adjuvant/neoadjuvant therapy more than two regiments. Received any investigational drug treatment within 30 days of start of study treatment. Patients with active gastrointestinal bleeding. Neurological toxicity ≥ grade 2 NCICTCAE. Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma. History or clinical evidence of brain metastases. Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes. Pregnancy women. Subjects with reproductive potential not willing to use an effective method of contraception. Patients with known active infection with HIV. Known hypersensitivity to any of the study drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>gastric cancer</keyword>
</DOC>